Can Serum IgG Antiganglioside Antibodies to GM1, GM3 and GD1a be Used as Markers in Patients with Ischemic Stroke?

Abstract

Our aim is to verify whether serum IgG antiganglioside antibodies (anti-GM1, anti-GD1a and anti-GM3) can be used as markers for patients with ischemic stroke. We showed the results of the antibody titer obtained by ELISA technique. There were 21 sera from patients under 75 years of age with ischemic strokes received between 2017-2020 from University First MHAT -Sofia, "St. John Krastitel". Three patients had a very weak indication for demyelination. Five had indication that correlates with possible metabolic abnormalities. The conclusion that could be drawn was that the antiganglioside antibodies titer was not decisive and could not be used as biomarker in stroke patients, and did not directly correlate with stroke severity, size of the ischemic area (reported by computed tomography data), and likely recovery prognosis. In ischemic strokes none of the patients had an indication of neuronal damage, as in the case with severe attacks of multiple sclerosis or Alzheimer's disease.